Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® (semaglutide 2.4mg), in Singapore.
The treatment received regulatory approval from Singapore’s Health Sciences Authority on 28 February 2025, and became available by private prescription from 12 July 2025.
Wegovy is approved for adults and adolescents aged 12 and above living with obesity (BMI ≥30) or who are overweight (BMI ≥27) with at least one weight-related condition such as hypertension or type 2 diabetes. It is intended to be used alongside a reduced-calorie diet and increased physical activity.
According to Novo Nordisk, Wegovy works by making individuals to feel full sooner and reduce food intake.
Singapore is estimated to have over 600,000 adults living with obesity. The launch adds a new option to the country’s tools for addressing the condition, which the World Health Organization recognizes as a chronic disease.
